carmofur has been researched along with Cancer of Liver in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg." | 7.67 | [Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 7.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
| "The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 7.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
| "HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 7.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
| "We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1." | 3.71 | Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg." | 3.67 | [Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984) |
| "1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 3.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
| "The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 3.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
| "HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 3.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
| "Before proceeding with a resection of a hepatocellular carcinoma (HCC) in patients, the concentrations of 5-FU and 1-Hexylcarbamoyl-5-fluorouracil (HCFU) have been measured in the serum, the liver, and in the cancer tissue after an oral administration of HCFU (300 mg)." | 3.67 | [5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration]. ( Suenaga, M, 1988) |
| "Though treatment of recurrent gastric cancer with liver metastasis is often ineffective, this case suggests that a combination therapy of cisplatin and carmofur might be effective." | 1.30 | [A case of recurrent gastric cancer with liver metastasis responding to combination chemotherapy with cisplatin and carmofur]. ( Inomata, Y; Inoue, K; Kuroda, T; Mizutani, H; Sakuyama, T; Tadaoka, N; Takahashi, N; Yamada, T; Yoshinaga, K, 1997) |
| " After right lobectomy of the liver which contained the tumors of S6 2 cm and S8 3 cm in diameter 7 months before, the patient was treated with hepatic arterial embolization (TAE) combined with infusion of anti-cancer drug (ADM, CDDP) four times since June 1990." | 1.28 | [A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE]. ( Imai, Y; Ito, J; Kobayashi, K; Okamoto, M; Tagawa, K; Taniguchi, M; Tanzawa, Y; Toda, N; Unuma, T; Uta, Y, 1992) |
| "Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin." | 1.27 | [Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma]. ( Hino, I; Kimura, I; Kuroda, S; Numoto, A; Ohnoshi, T; Takahashi, M; Tsuji, M; Ueoka, H, 1984) |
| "407 cases of unresectable hepatocellular carcinoma (HCC) occurring from 1970 to March 1985, including 107 cases receiving conservative therapy, 176 cases receiving one-shot therapy and 124 cases receiving transcatheter arterial embolization (TAE) therapy, were studied and the efficacy of chemotherapy was compared with that of TAE therapy." | 1.27 | [One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kawazoe, Y; Kumagai, M; Tanikawa, K; Yamashita, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (42.31) | 18.7374 |
| 1990's | 12 (46.15) | 18.2507 |
| 2000's | 3 (11.54) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osterlund, P | 1 |
| Orpana, A | 1 |
| Elomaa, I | 1 |
| Repo, H | 1 |
| Joensuu, H | 1 |
| Watanabe, M | 1 |
| Kodaira, S | 1 |
| Takahashi, T | 2 |
| Tominaga, T | 1 |
| Hojo, K | 2 |
| Kato, T | 1 |
| Kunitomo, K | 1 |
| Isomoto, H | 1 |
| Ohashi, Y | 1 |
| Yasutomi, M | 1 |
| Shiraishi, K | 1 |
| Kubo, Y | 1 |
| Majima, Y | 1 |
| Sato, K | 1 |
| Sakemi, T | 1 |
| Sakai, T | 1 |
| Hirai, K | 2 |
| Ninomiya, F | 1 |
| Abe, M | 2 |
| Tanikawa, K | 2 |
| Akiharu, W | 1 |
| Higashi, T | 1 |
| Kobayashi, M | 1 |
| Nakatsukasa, H | 1 |
| Fujiwara, M | 1 |
| Shiota, T | 1 |
| Yamauchi, Y | 1 |
| Ito, T | 1 |
| Yamamoto, H | 1 |
| Nagashima, H | 1 |
| Ueoka, H | 1 |
| Kuroda, S | 1 |
| Ohnoshi, T | 1 |
| Kimura, I | 1 |
| Numoto, A | 1 |
| Hino, I | 1 |
| Takahashi, M | 2 |
| Tsuji, M | 1 |
| Itsubo, M | 1 |
| Yamamoto, M | 1 |
| Arii, S | 1 |
| Sugahara, K | 1 |
| Tobe, T | 1 |
| Fujii, Y | 2 |
| Itoyanagi, H | 1 |
| Hirose, I | 1 |
| Hasumi, K | 2 |
| Eriguchi, M | 2 |
| Tadaoka, N | 1 |
| Takahashi, N | 1 |
| Yoshinaga, K | 1 |
| Yamada, T | 1 |
| Inoue, K | 1 |
| Mizutani, H | 1 |
| Inomata, Y | 1 |
| Sakuyama, T | 1 |
| Kuroda, T | 1 |
| Ono, T | 2 |
| Nagasue, N | 3 |
| Kohno, H | 3 |
| Hayashi, T | 1 |
| Uchida, M | 1 |
| Yukaya, H | 2 |
| Yamanoi, A | 2 |
| Maeda, M | 1 |
| Nagawa, H | 1 |
| Maeda, T | 1 |
| Koike, H | 1 |
| Kasai, H | 1 |
| Matsuda, T | 1 |
| Mabuchi, K | 1 |
| Kitaoka, H | 1 |
| Hirata, N | 1 |
| Kitaoka, U | 1 |
| Iwasa, H | 1 |
| Hirai, J | 1 |
| Nazmy El Assal, O | 1 |
| Imai, Y | 1 |
| Ito, J | 1 |
| Tanzawa, Y | 1 |
| Toda, N | 1 |
| Okamoto, M | 1 |
| Kobayashi, K | 1 |
| Taniguchi, M | 1 |
| Uta, Y | 1 |
| Tagawa, K | 1 |
| Unuma, T | 1 |
| Okuyama, K | 1 |
| Awano, T | 1 |
| Tohnosu, N | 1 |
| Koide, Y | 1 |
| Matsubara, H | 1 |
| Nakaichi, H | 1 |
| Funami, Y | 1 |
| Matsushita, K | 1 |
| Amano, H | 1 |
| Ochiai, T | 1 |
| Chang, YC | 1 |
| Nakamura, T | 1 |
| Ogawa, Y | 1 |
| Sasaki, K | 1 |
| Moriya, Y | 1 |
| Sugihara, K | 1 |
| Makuuchi, M | 1 |
| Kanda, Y | 1 |
| Akazawa, S | 1 |
| Futatsugi, K | 1 |
| Fujiki, T | 1 |
| Saifuku, K | 1 |
| Yamamoto, K | 1 |
| Suzuki, F | 1 |
| Nakajima, T | 1 |
| Naoi, Y | 1 |
| Muraoka, M | 1 |
| Takenaka, K | 2 |
| Kanematsu, T | 2 |
| Shimada, M | 1 |
| Sugimachi, K | 2 |
| Mori, M | 1 |
| Hamazaki, K | 1 |
| Mimura, H | 1 |
| Orita, K | 1 |
| Higashi, H | 1 |
| Matsumata, T | 1 |
| Yoshida, Y | 1 |
| Suenaga, M | 1 |
| Taniguchi, H | 1 |
| Shioaki, Y | 1 |
| Itoh, A | 1 |
| Seiki, K | 1 |
| Shimotsuma, M | 1 |
| Yamaguchi, T | 1 |
| Sawai, K | 1 |
| Kitai, S | 1 |
| Shimamura, Y | 1 |
| Kawazoe, Y | 1 |
| Yamashita, K | 1 |
| Kumagai, M | 1 |
| Onji, M | 1 |
| Kondo, H | 1 |
| Yamashita, Y | 1 |
| Ohta, Y | 1 |
| Mori, K | 1 |
| Fuse, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carmofur and Cancer of Liver
| Article | Year |
|---|---|
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa | 2001 |
4 trials available for carmofur and Cancer of Liver
| Article | Year |
|---|---|
Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Com | 2006 |
Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Flu | 1996 |
Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1997 |
[Oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in repeated arterial bolus chemotherapy in metastatic liver cancer of humans--preliminary randomized trial].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorub | 1991 |
21 other studies available for carmofur and Cancer of Liver
| Article | Year |
|---|---|
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorou | 1984 |
[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 1984 |
[Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma].
Topics: Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Sched | 1984 |
[The present status of chemotherapy for hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1993 |
[Characterization of spontaneous liver metastatic model of BALB/c retroperitoneal sarcoma (LMFS) injected in footpad and antitumor effects of HCFU].
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Liver; Liver Neoplasms; Mic | 1997 |
[A case of recurrent gastric cancer with liver metastasis responding to combination chemotherapy with cisplatin and carmofur].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluor | 1997 |
Alcohol consumption enhances liver metastasis in colorectal carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Analysis of Variance; Antineoplastic Agents; Blood | 1998 |
[A case of multiple liver metastases showing good response by administration of carmofur alone in an aged patient with colorectal cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neopla | 1999 |
[Effects of HCFU and TNP 470 on liver metastasis of BALB/c retroperitoneal sarcoma (LMFS)].
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cyclohexanes; | 1999 |
[A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeut | 1992 |
[Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubi | 1992 |
Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 1991 |
[A case of hepatocellular carcinoma (HCC) with lung metastasis which responded to chemotherapy with a single use of 1-hexylcarbamoyl-5-fluorouracil (HCFU)].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Lung Neopla | 1989 |
Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Liver Cirrhosis; Liv | 1989 |
[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1989 |
[1-Hexylcarbamoyl-5-fluorouracil (HCFU) effective in hepatocellular carcinoma metastatic to the lungs--a case report].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1987 |
[5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration].
Topics: Administration, Oral; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver; Liver Neoplasms | 1988 |
[Trans-arterial embolization or transarterial infusion of anti-cancer drugs suspended in a lipid contrast medium against unresectable metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Embolization, Therapeutic; Fluorouracil | 1988 |
[One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Embolization | 1985 |
[Blood level of 5-fluorouracil (5-FU) by oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and tegafur in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1985 |